CNTX logo

CNTX
Context Therapeutics Inc

5,232
Mkt Cap
$228.78M
Volume
519,448.00
52W High
$3.62
52W Low
$0.49
PE Ratio
-6.48
CNTX Fundamentals
Price
$2.49
Prev Close
$2.59
Open
$2.60
50D MA
$2.61
Beta
0.97
Avg. Volume
971,196.12
EPS (Annual)
-$0.3795
P/B
3.78
Rev/Employee
$0.00
$74.04
Loading...
Loading...
News
all
press releases
Neogen Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary
Neogen Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. Ms. Stacey is an accomplished chief legal and compliance officer and board secretary with extensive...
Business Wire·3d ago
News Placeholder
More News
News Placeholder
Context Therapeutics (NASDAQ:CNTX) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen downgraded Context Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...
MarketBeat·14d ago
News Placeholder
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine research firms that are currently covering the stock, MarketBeat...
MarketBeat·15d ago
News Placeholder
Q1 EPS Forecast for Context Therapeutics Lowered by Analyst
Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Equities research analysts at Lifesci Capital reduced their Q1 2026 earnings per share estimates for Context Therapeutics in a report issued on...
MarketBeat·15d ago
News Placeholder
HC Wainwright Brokers Reduce Earnings Estimates for CNTX
Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Research analysts at HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for Context Therapeutics in a research report...
MarketBeat·17d ago
News Placeholder
Context Therapeutics' (CNTX) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital restated a "buy" rating and set a $9.00 price target on shares of Context Therapeutics in a research report on Tuesday...
MarketBeat·18d ago
News Placeholder
Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from Guggenheim
Guggenheim restated a "buy" rating and issued a $5.00 target price on shares of Context Therapeutics in a research note on Tuesday...
MarketBeat·18d ago
News Placeholder
Context Therapeutics (NASDAQ:CNTX) Price Target Raised to $7.00
Piper Sandler lifted their price objective on shares of Context Therapeutics from $4.00 to $7.00 and gave the stock an "overweight" rating in a research note on Tuesday...
MarketBeat·18d ago
News Placeholder
Context Therapeutics (NASDAQ:CNTX) Issues Earnings Results
Context Therapeutics (NASDAQ:CNTX - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus...
MarketBeat·19d ago
News Placeholder
Context Therapeutics (NASDAQ:CNTX) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised Context Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·22d ago
<
1
2
...
>

Latest CNTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.